IDH1 and acute myeloid leukemia: It is currently approved by the FDA to treat adult patients with relapsed or refractory AML carrying an IDH1 mutation as detected by an FDA-approved test (AG-120, Tibsovo; Agios Pharmaceuticals, Inc., MA, USA (Food and Drug Administration, 2018)).